Background: Cerebral palsy is the most common cause of physical disability in childhood. Spasticity is a significant contributor to the secondary impairments impacting functional performance and participation. The most common lower limb spasticity management is focal intramuscular injections of Botulinum Toxin-Type A accompanied by individually-delivered (one on one) physiotherapy rehabilitation. With increasing emphasis on improving goal-directed functional activity and participation within a family-centred framework, it is timely to explore whether physiotherapy provided in a group could achieve comparable outcomes, encouraging providers to offer flexible models of physiotherapy delivery. This study aims to compare individual to group-bas...
Contains fulltext : 80828.pdf (publisher's version ) (Closed access)BACKGROUND: Re...
Background & objectives: Botulinum toxin is considered as an effective treatment for spasticity in c...
Item does not contain fulltextAIM: To assess treatment effects of botulinum toxin type A (BoNT-A) on...
This study aimed to evaluate efficacy of group (GRP) versus individual (IND) physiotherapy rehabilit...
textabstractObjective: Despite the widespread use of botulinum toxin in ambulatory children with spa...
Objectives: To investigate whether botulinum toxin type A (BTX-A) injection is more effective than r...
Background Intramuscular injections of botulinum toxin A (BoNT-A) have been a cornerstone in the tre...
The main goal of this study was to investigate the efficacy of Botulinum Toxin A (BoNT-A), combined ...
BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination w...
Abstract Background Children with cerebral palsy (CP) whom are non-ambulant are at risk of reduced q...
International audienceBACKGROUND: Dystonia and spasticity are common symptoms in children with Cereb...
Background: A cost-effectiveness trial (the Space Bop study) on the added value of botulinum toxin i...
BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination w...
Background: A cost-effectiveness trial (the Space Bop study) on the added value of botulinum toxin i...
Objective: To evaluate the combined effect on mobility of treatment with multilevel botulinum toxin ...
Contains fulltext : 80828.pdf (publisher's version ) (Closed access)BACKGROUND: Re...
Background & objectives: Botulinum toxin is considered as an effective treatment for spasticity in c...
Item does not contain fulltextAIM: To assess treatment effects of botulinum toxin type A (BoNT-A) on...
This study aimed to evaluate efficacy of group (GRP) versus individual (IND) physiotherapy rehabilit...
textabstractObjective: Despite the widespread use of botulinum toxin in ambulatory children with spa...
Objectives: To investigate whether botulinum toxin type A (BTX-A) injection is more effective than r...
Background Intramuscular injections of botulinum toxin A (BoNT-A) have been a cornerstone in the tre...
The main goal of this study was to investigate the efficacy of Botulinum Toxin A (BoNT-A), combined ...
BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination w...
Abstract Background Children with cerebral palsy (CP) whom are non-ambulant are at risk of reduced q...
International audienceBACKGROUND: Dystonia and spasticity are common symptoms in children with Cereb...
Background: A cost-effectiveness trial (the Space Bop study) on the added value of botulinum toxin i...
BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination w...
Background: A cost-effectiveness trial (the Space Bop study) on the added value of botulinum toxin i...
Objective: To evaluate the combined effect on mobility of treatment with multilevel botulinum toxin ...
Contains fulltext : 80828.pdf (publisher's version ) (Closed access)BACKGROUND: Re...
Background & objectives: Botulinum toxin is considered as an effective treatment for spasticity in c...
Item does not contain fulltextAIM: To assess treatment effects of botulinum toxin type A (BoNT-A) on...